The soluble interleukin 6 receptor: Mechanisms of production and implications in disease

FASEB Journal

Volumn 15, Issue 1, 2001, Pages 43-58

  Jones, S A ^a   Horiuchi, S ^a   Topley, N ^a   Yamamoto, N ^a   Fuller, G M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cytokines; Inflammation; Interleukin 6; Shedding; Soluble receptors

Indexed keywords

AUTACOID; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CROHN DISEASE; CYTOKINE PRODUCTION; DIMERIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RNA SPLICING; SEQUENCE ANALYSIS;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; ARTHRITIS; BASE SEQUENCE; CELL DIFFERENTIATION; CELL DIVISION; CROHN DISEASE; DISEASE; HUMANS; INTERLEUKIN-6; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; PROTEIN ISOFORMS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; SOLUBILITY;

EID: 0035164602     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.99-1003rev     Document Type: Review

References (178)

1. Interleukin-6 family of cytokines and gp130
2. Increased osteoclast development after estrogen loss: Mediated by interleukin-6
3. Human atherosclerotic abdominal aortic aneurysms produce interleukin-6 and interferon-gamma, but not IL-2 and IL4: The possible role for interleukin-6 and interferon-gamma in vascular inflammation
4. Cytokine signaling during myocardial infarction: Sequential appearance of IL-1 beta and IL-6
5. Involvement of interleukin-6 in mesangial proliferative glomerulonephritis
6. Correlation of synovial fluid interleukin-6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis
7. Increased plasma levels of interleukin-6 in sepsis
8. Interleukin-6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with TNF-α by transcriptional and post-transcriptional mechanisms
9. Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model
10. Intratracheal injection of endotoxin and cytokines. Interleukin-6 and transforming growth factor beta inhibit acute inflammation
11. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses
12. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human mononuclear cells: IL-6 suppresses IL-1 and TNF
13. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
14. Molecular cloning of a murine IL-6 receptor-associated signal transducer gp130, and its regulated expression in vivo
15. Interleukin-11 regulates the hepatic expression of the same plasma-protein genes as interleukin-6
16. Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin-6 signal transducer gp130
17. Cardiotrophin-1: Biological activities and binding to the leukemia inhibitory factor-receptor gp130 signaling complex
18. Novel neurotrophin-1/B-cell stimulating factor-3: A cytokine of the IL-6 family
19. Disruption of the CNTF gene results in motor-neuron degeneration
20. Impaired immune and acute-phase responses in interleukin-6-deficient mice
21. Leukemia inhibitory factor is necessary for the maintenance of hematopoietic stem-cells and thymocyte stimulation
22. Targeted disruption of gp130 a common signal transducer for the interleukin-6 family of cytokines leads to myocardial and hematological disorders
23. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase
24. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130
25. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors
26. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the IL-6 signal transducer gp130. Definition of a novel phosphotyrosine motif mediating STAT1 activation
27. LIFR-β and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor
28. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors
29. Phosphorylation at theonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL-6
30. Involvement of Janus kinase p52shc, Raf-1 and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B-cell line
31. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
32. Association of p72 tyrosine kinase with STAT factors and its activation by interleukin-3, interleukin-6 and granulocyte colony stimulating factor
33. Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells
34. Activation of Fes tyrosine kinase by gp130, an interleukin-6 family cytokine signal transducer, and their association
35. Association and activation of Btk and Tec kinases by gp130, a signal transducer of the interleukin-6 family of cytokines
36. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
37. Soluble cytokine receptors are present in normal human urine
38. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection
39. A soluble interleukin-6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA
40. Soluble IL-6 receptor potentiates the antagortistic activity of soluble gp130 on IL-6 responses
41. The function of the soluble IL-6 receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
42. Soluble receptors for cytokines and growth factors: Their generation and biological function
43. Released form of CNTF receptor-alpha component as a soluble mediator of CNTF responses
44. Functional expression of soluble human interleukin-11 (IL-11) receptor α and stoichiometry of in vitro IL-11 receptor complexes with gp130
45. A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130
46. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor
47. Interleukin-6 triggers the association of its receptor with a possible signal transducer gp130
48. Molecular cloning and expression of an IL-6 signal transducer, gp130
49. Soluble human interleukin-6-receptor modulates interleukin-6-dependent N-glycosylation of α1-protease inhibitor secreted by HepG2 cells
50. Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing
51. The soluble form of the IL-6 receptor (sIL-6Rα) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R-induced AIDS-KS cell growth
52. gp130 and c-kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells
53. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor
54. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice
55. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver
56. Interleukin-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells, but not on osteoclast progenitors
57. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from arthritis patients are responsible for osteoclast-like cell formation
58. Soluble IL-6 receptor triggers osteoclast formation by interleukin-6
59. Extramedullary expansion of hematopoietic progenitor cells in interleukin IL-6-sIL-6R double transgenic mice
60. Interleukin-6 and soluble interleukin-6 receptor: Direct stimulation of gp130 and hematopoiesis
61. Is IL-6 both a cytokine and a neurotrophic factor?
62. Accelerated nerve regeneration in mice by upregulated expression of interleukin-6 (IL-6) and IL-6 receptor after trauma
63. Sympathetic neurons can produce and respond to interleukin-6
64. Induction of myelin gene expression in Schwann cell cultures by an interleukin-6 receptor-interleukin-6 chimera
65. Continuous activation of gp130, a signal-transducing receptor component for interleukin-6-related cytokines, causes myocardial hypertrophy in mice
66. Targeted disruption of gp130, a common signal transducer for the interleukin-6 family of cytokines, leads to myocardial and hematological disorders
67. Expression cloning of cardiotrophin-1, a cytokine that induces cardiac myocyte hypertrophy
68. Leukemia inhibitory factor: A cytokine at the interface between neurobiology and immunology
69. Cardiotrophin-1 induces the same neuropeptides in sympathetic neurons as do cytokines
70. The role of gp130-mediated signals in osteoclast development: Regulation of interleukin-11 production by osteoblasts and distribution of its receptor in bone marrow cultures
71. + cells
72. + cells through glycoprotein 130 signaling
73. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment
74. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha
75. Concentrations and origins of soluble interleukin-6 receptor-α in serum and synovial fluid
76. Effect of soluble interleukin-6 synthesis in human skin fibroblasts
77. Novel path to activation of vascular smooth muscle cells: Up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor
78. Interleukin-6 and transforming growth factor-beta regulate the expression of monocyte chemoattractant protein-1 and colony-stimulating factors in human thyroid follicular cells
79. Interleukin-6 (IL-6) production by astrocytes: Autocrine regulation by IL-6 and the soluble IL-6 receptor
80. Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression
81. Cytokine regulation of CC and CXC chemokine expression by human astrocytes
82. Interleukin-6 and its soluble receptor cause a marked induction of collagenase 3 expression in rat osteoblast cultures
83. Interleukin-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity
84. Soluble interleukin-6 receptor augments central effects of IL-6 in vivo
85. Soluble IL-6 receptor leads to a paracrine modulation of IL-6-induced hepatic acute phase response in double transgenic mice
86. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor
87. Release of the soluble interleukin-6 receptor form human T-cells
88. C-reactive protein: A physiological activator of IL-6 receptor shedding
89. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
90. Soluble interleukin-6 receptors released from T cells or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism
91. A soluble interleukin-6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA
92. High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-1-associated myelopathy
93. Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternate splicing
94. Cytokines oncostatin-M and interleukin-1 regulate expression of the IL-6 receptor (gp80, gp130)
95. Oncostatin-M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells
96. Protein kinase C activity is rate limiting for the shedding of the interleukin-6 receptor
97. The soluble interleukin-6 receptor is generated by shedding
98. The soluble human IL-6 receptor: Mutational characterization of the proteolytic cleavage site
99. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
100. 2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells
101. Human myeloma cells shed the interleukin-6 receptor: Inhibition by tissue inhibitor of metalloproteinase-3 and hydroxamate-based metalloproteinase inhibitor
102. A metalloprotease inhibitor blocks shedding of the 75-kD TNF receptor and TNF processing in T-lymphocytes
103. Neutrophil rolling altered by inhibition of L-selectin shedding in vitro
104. Hydroxamic-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes: Functional consequences for neutrophil aggregation
105. Pore-forming toxins trigger shedding of receptors for interleukin-6 and lipopolysaccharide
106. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors
107. Apical enrichment of human EGF precursor in Madin-Darby canine cells involves preferential basolateral ectodomain cleavage sensitive to a metalloprotease inhibitor
108. Novel pathogenic mechanism of microbial metalloproteinases: Liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor
109. A metalloprotease disintegrin that releases tumour-necrosis factor-α from cells
110. Cloning of a disintegrin metalloprotease that processes tumour necrosis factor-α
111. An essential role for ectodomain shedding in mammalian development
112. Identification and characterization of a protumor necrosis factor-α-processing enzyme from the ADAM family of zinc metalloproteases
113. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein
114. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines
115. Human C-reactive protein inhibits neutrophil chemotaxis in vitro: Possible implications for adult respiratory distress syndrome
116. Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor
117. The major receptor for C-reactive protein on leukocytes is Fcγ receptor II
118. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein
119. Proteolytic cleavage of ICAM-1 by human neutrophil elastase
120. Proteolysis of monocyte CD14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation
121. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3
122. Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation
123. Myeloma cells release soluble interleukin-6R alpha in relation to disease progression by two distinct mechanisms: Alternative splicing and proteolytic cleavage
124. The membrane proximal cytokine receptor domain of human interleukin-6 receptor is sufficient for ligand binding but not for gp130 association
125. Yeast expression of the cytokine domain of the soluble interleukin-6 receptor
126. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130
127. Characterization of a soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin-6 family
128. LIF and OM directly interact with a soluble form of gp130, the IL-6 receptor signal transducing subunit
129. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma
130. Differential shedding of the two subunits of the interleukin-6 receptor
131. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130
132. Elevated serum levels of the soluble form of gp130, the IL-6 signal transducer, in HTLV-1 infection and no involvement of alternative splicing for its generation
133. Interleukin-6 in synovial fluid and serum patients with rheumatoid arthritis and other inflammatory arthritis
134. Synovium as a source of interleukin-6 in vivo. Contribution to local and systemic manifestations of arthritis
135. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis
136. Interleukin-6 is required for the development of collagen-induced arthritis
137. Interleukin-6 plays a key role in the development of antigen-induced arthritis
138. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
139. Interleukin-6 knock-out mice are resistant to antigen-induced experimental arthritis
140. Treatment of severe rheumatoid arthritis by ant-interleukin-6 monoclonal antibody
141. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts
142. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis
143. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis
144. Effects of IL-6 and its soluble receptor on proteoglycan synthesis and NO release by human articular chondrocytes: Comparison with IL-1. Modulation by dexamethasone
145. The biology of interleukin-6
146. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma
147. Interleukin-6 prevents dexamethasone-induced myeloma cell death
148. Interleukin-6 is a prognostic factor in multiple myeloma
149. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy
150. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias
151. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma
152. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma
153. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein
154. Major role of the soluble interleukin-6/interleukin-6R complex for the proliferation of interleukin-6-dependent human myeloma cell lines
155. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2)
156. Soluble interleukin-6 receptors in inflammatory bowel disease: Relation to circulating interleukin-6
157. IL-6 is required for the development of Th1 cell-mediated murine colitis
158. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn's disease and experimental colitis in vivo
159. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta2) receptor
160. Circulating interleukin-6 receptor in patients with sepsis syndrome
161. Circulating levels of soluble interleukin-6 receptor in patients with bronchial asthma
162. Elevation of soluble IL-6 receptor concentrations in serum and epithelial lining fluid from patients with interstitial lung disease
163. Enhanced production of interleukin-6 (IL-6), oncostatin-M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis
164. Interleukin-6 and its soluble receptor are elevated in aqueous humor of patients with uveitis
165. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease
166. Interleukin-6 and soluble interleukin-6 receptor in pentoneal fluid and serum of patients with endometriosis
167. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients
168. Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease
169. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: No alteration in soluble gp130
170. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis
171. Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers
172. Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma
173. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder after accidental man-made traumatic events
174. Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment
175. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer
176. Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria
177. Soluble interleukin-6 receptor, interleukin-10 and granulocyte colony-stimulating factor in acute pyelonephritis: Relationship to markers of bacterial virulence and renal function
178. Interleukin-6 and its soluble receptor during acute meningococcal infections: Effect of plasma or whole blood exchange